Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Total Revenue of $3.71 billion for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $3.71B +65.2% |
$2.25B +23.0% |
$1.83B +76.2% |
$1.04B +22.9% |
$844.29M +71.3% |
$492.85M +124.3% |
| Revenue (ASC 606) | $3.71B +65.2% |
$2.25B +23.0% |
$1.83B +76.2% |
$1.04B +22.9% |
$844.29M +71.3% |
$492.85M +124.3% |
| Net Income | $313.75M +212.8% |
-$278.16M +36.8% |
-$440.24M +61.1% |
-$1.13B -32.6% |
-$852.82M +0.6% |
-$858.28M +3.1% |
| Diluted EPS | $2.33 +206.9% |
-$2.18 +38.1% |
-$3.52 +62.2% |
-$9.30 -29.2% |
-$7.20 +3.5% |
-$7.46 +8.0% |
| Total Assets | $4.97B +17.1% |
$4.24B +10.7% |
$3.83B +8.0% |
$3.55B -2.7% |
$3.64B +6.9% |
$3.41B +42.2% |
| Cash and Equivalents | $1.66B +71.5% |
$966.43M +18.9% |
$812.69M -6.2% |
$866.39M +5.7% |
$819.98M +65.1% |
$496.58M -9.2% |
| Stockholders Equity | $789.18M +1076.3% |
$67.09M +130.4% |
-$220.64M -39.5% |
-$158.22M -126.9% |
$588.20M -42.1% |
$1.02B -29.4% |
| R&D Expense | $1.32B +17.2% |
$1.13B +12.1% |
$1.00B +13.7% |
$883.01M +11.5% |
$792.16M +21.0% |
$654.82M -0.0% |
| Operating Income | $501.58M +383.6% |
-$176.88M +37.3% |
-$282.18M +64.1% |
-$785.07M -10.8% |
-$708.65M +14.5% |
-$828.44M +11.8% |
| Shares Outstanding | 132.38M +2.4% |
129.29M +2.8% |
125.79M +1.5% |
123.92M +3.1% |
120.18M +3.2% |
116.43M +3.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.25B | +149.3% | +61.4% |
| Revenue (ASC 606) | September 30, 2025 | $1.25B | +149.3% | +61.4% |
| Net Income | September 30, 2025 | $251.08M | +325.0% | +478.8% |
| Diluted EPS | September 30, 2025 | $1.84 | +311.5% | +460.8% |
| Total Assets | September 30, 2025 | $4.85B | +15.4% | +6.3% |
| Cash and Equivalents | September 30, 2025 | $1.49B | +35.5% | +33.8% |
| Long-Term Debt | June 30, 2022 | $677.72M | +56.5% | +0.1% |
| Stockholders Equity | September 30, 2025 | $233.89M | +622.9% | -6.7% |
| R&D Expense | September 30, 2025 | $358.81M | +32.4% | +10.9% |
| Operating Income | September 30, 2025 | $367.98M | +578.5% | +2371.6% |
| Shares Outstanding | September 30, 2025 | 131.79M | +2.3% | +0.6% |
- ALNYLAM PHARMACEUTICALS, INC. reported Total Revenue of $3.71 billion for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +65.2% in Total Revenue compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $3.71 billion for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +65.2% in Revenue (ASC 606) compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported Net Income of $313.75 million for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +212.8% in Net Income compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported Diluted EPS of $2.33 per share for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +206.9% in Diluted EPS compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported Total Assets of $4.97 billion for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +17.1% in Total Assets compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported Cash and Equivalents of $1.66 billion for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +71.5% in Cash and Equivalents compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported Stockholders Equity of $789.18 million for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +1076.3% in Stockholders Equity compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported R&D Expense of $1.32 billion for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +17.2% in R&D Expense compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported Operating Income of $501.58 million for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +383.6% in Operating Income compared to the prior fiscal year.
- ALNYLAM PHARMACEUTICALS, INC. reported Shares Outstanding of 132.38 million shares for fiscal year 2025.
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +2.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: